Cardarine, Also known as GW-501516 powder is a research chemical classed as a PPAR receptor agonist. Often mistakenly lumped into the SARMs category, cardarine has been considered heavily as an option for treating ailments such as high cholesterol and other metabolic-related issues like obesity and diabetes.
02 GW501516 (Cardarine) powder video
03 GW501516 (Cardarine) Base Information
|Name||GW501516 (Cardarine) powder|
|Synonyms||GW501516; GW-501516; GW 501516; GW1516; GW 1516; GW-1516; GSK-516; GSK 516; GSK516; Endurobol.|
|Molecular Weight||453.494 g/mol|
|Melting Point||144.2-146.1 ℃|
|Half Life||roughly 12-24|
|Solubility||Soluble in DMSO, not in water|
|Storage Condition||0 – 4 C for short term (days to weeks), or -20 C for long term (months).|
|Application||Cardarine was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases,|
04 GW501516 (Cardarine) General Description
GW501516 powder is a receptor agonist ,was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases,
05 GW501516 (Cardarine) powder History
Cardarine (GW-501516) powder first was developed in the early 1990’s by Ligand and GlaxoSmithKline as an anti-tumor drug. They also found out it worked well for lipid/heart health during the early trials and then how effective it was for endurance, diabetes, and getting rid of fat. It is not known why the drug was abandoned but that did not stop athletes from using it to dope, and today it is one of the most popular performance-enhancing drugs being sold to those in fitness.
06 GW501516 (Cardarine) Mechanism of action
Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.
07 GW501516 (Cardarine) Application
GW 501516 is an aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively. It has a role as a PPARbeta/delta agonist and a carcinogenic agent. It is a monocarboxylic acid, a member of 1,3-thiazoles, an organofluorine compound, an aryl sulfide and an aromatic ether.
08 GW501516 (Cardarine) Document Download
09 GW501516 (Cardarine) Reference
1: Chen W, Gao R, Xie X, Zheng Z, Li H, Li S, Dong F, Wang L. A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884. doi: 10.1038/srep09884. PubMed PMID: 25943561; PubMed Central PMCID: PMC4421799.
2: Magliano DC, Penna-de-Carvalho A, Vazquez-Carrera M, Mandarim-de-Lacerda CA, Aguila MB. Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system. Endocrine. 2015 Nov;50(2):355-67. doi: 10.1007/s12020-015-0590-1. Epub 2015 Apr 9. PubMed PMID: 25854303.
3: Wang X, Sng MK, Foo S, Chong HC, Lee WL, Tang MB, Ng KW, Luo B, Choong C, Wong MT, Tong BM, Chiba S, Loo SC, Zhu P, Tan NS. Early controlled release of peroxisome proliferator-activated receptor β/δ agonist GW501516 improves diabetic wound healing through redox modulation of wound microenvironment. J Control Release. 2015 Jan 10;197:138-47. doi: 10.1016/j.jconrel.2014.11.001. Epub 2014 Nov 7. PubMed PMID: 25449811.
- 01. Overview
- 02. GW501516 (Cardarine) powder video
- 03. GW501516 (Cardarine) Base Information
- 04. GW501516 (Cardarine) General Description
- 05. GW501516 (Cardarine) powder History
- 06. GW501516 (Cardarine) Mechanism of action
- 07. GW501516 (Cardarine) Application
- 08. GW501516 (Cardarine) Document Download
- 09. GW501516 (Cardarine) Reference